Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells.

Adriana AmaroFrancesco ReggianiDaniela FenoglioRosaria GangemiAnna TosiAlessia ParodiBarbara BanelliValentina RigoLuca MastracciFederica GrilloAlessandra CereghettiAizhan TastanovaAdhideb GhoshFabio SallustioLaura EmioniteAntonio DagaTiziana AltosoleGilberto FilaciAntonio RosatoMitchell LevesqueMichele MaioUlrich PfefferMichela Crocenull null

Published in: Journal of experimental & clinical cancer research : CR (2023)

These results indicate Guadecitabine as a promising epigenetic drug to be added to ICBs therapy.

Keyphrases

nk cells
dna methylation
gene expression
bone marrow
drug induced
skin cancer
smoking cessation